Citius Pharmaceuticals (CTXR) Assets (2011 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Assets came in at $132.5 million in Q1 2026, up 9.1% YoY from $121.5 million in Q1 2025, and down 5.59% on a QoQ basis from $140.4 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Assets (2011 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 16 years of Assets data on file, last reported at $132.5 million in Q1 2026.
- Quarterly Assets rose 9.1% year-over-year to $132.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $132.5 million (up 9.1% YoY) and the FY2025 annual result came in at $130.9 million, up 12.25% from the prior year.
- Assets retreated to $132.5 million in Q1 2026, from $140.4 million in the prior quarter.
- In the past five years, Assets ranged from a high of $140.4 million in Q4 2025 to a low of $90.7 million in Q1 2024.
- A 5-year average of $115.7 million and a median of $116.7 million in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets slipped 19.96% — and 2025, when it surged 33.92%.
- Tracing CTXR's Assets over 5 years: stood at $111.7 million in 2022, then fell by 12.81% to $97.4 million in 2023, then climbed by 23.93% to $120.7 million in 2024, then climbed by 16.31% to $140.4 million in 2025, then retreated by 5.59% to $132.5 million in 2026.
- The last three Assets figures came in at $132.5 million (Q1 2026), $140.4 million (Q4 2025), and $130.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Citius Pharmaceuticals | 15.71 Mn | 15.71 Mn | 1.00 Mn | 142.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 132.54 Mn |
| Dec 31, 2025 | 140.39 Mn |
| Sep 30, 2025 | 130.94 Mn |
| Jun 30, 2025 | 127.68 Mn |
| Mar 31, 2025 | 121.48 Mn |
| Dec 31, 2024 | 120.70 Mn |
| Sep 30, 2024 | 116.65 Mn |
| Jun 30, 2024 | 97.09 Mn |
| Mar 31, 2024 | 90.71 Mn |
| Dec 31, 2023 | 97.40 Mn |
| Sep 30, 2023 | 103.61 Mn |
| Jun 30, 2023 | 110.40 Mn |
| Mar 31, 2023 | 104.24 Mn |
| Dec 31, 2022 | 111.71 Mn |
| Sep 30, 2022 | 114.00 Mn |
| Jun 30, 2022 | 120.32 Mn |
| Mar 31, 2022 | 127.79 Mn |
| Dec 31, 2021 | 137.52 Mn |
| Sep 30, 2021 | 142.43 Mn |
| Jun 30, 2021 | 146.59 Mn |